[Non-leukemic disease of the central nervous system in children with acute lymphoblastic leukemia. I. Somnolence syndrome (author's transl)].
Prophylactic irradiation of the skull and intrathecal application of methotrexate has proven to be highly effective in preventing central nervous system disease in acute lymphoblastic leukemia or non-Hodgkin-lymphoma. Prophylactic treatment may be complicated by a somnolence syndrome occuring 4--8 weaks after the end of irradiation. The main features of this clinical entity are somnolence, lethargy, dullness, anorexia, headache, and vomiting. EEG frequently displays a distinct slowing of activity. All symptoms are reversible after 3--49 days. The syndrome clearly is consequence of skull irradiation. Its metabolic basis probably is transient disturbance of myelinization.
D000855:Anorexia / Q000139:chemically induced; D002648:Child; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced; D004569:Electroencephalography; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D001523:Mental Disorders / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects*; D009185:Myelin Proteins / Q000378:metabolism; D019965:Neurocognitive Disorders / Q000139:chemically induced*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D009185:Myelin Proteins; D008727:Methotrexate
Cerebrale Komplikationen der Leukämiebehandlung. I. Das Apathiesyndrom.